c-ABL-IN-4

• UNSPSC Description:

  c-ABL-IN-4 is a potent inhibitor of c-Abl. Activation of c-Abl has been implicated in various diseases, notably cancer. c-ABL-IN-4 has the potential for the research of neurodegenerative diseases (amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD) and cancer (extracted from patent WO2021048567A1, compound 54)[1].

• Target Antigen:

  Others

• Type:

  Reference compound

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/c-abl-in-4.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(C1=CN(C(C=C1)=O)C2=CN=CC(F)=C2)NC3=CC=C(C=C3)OC(F)(Cl)F

• Molecular Weight:

  409.75

• References & Citations:

  [1] Michael J. RAWLING, et al. New compounds and methods. Patent WO2021048567A1.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2626934-68-5